Welcome to our dedicated page for Starling Oncology SEC filings (Ticker: DFPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Starling Oncology's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Starling Oncology's regulatory disclosures and financial reporting.
Starling Oncology, Inc. (STLN) reported a board-level change. On September 1, 2026, director Brad Hively notified the company that he will not stand for re-election to the Board at the 2027 annual meeting of stockholders. He is expected to remain a director until that meeting but, effective immediately, no longer serves as Vice Chairman of the Board or as a member of the Compliance Committee or any other board committees. The company states that his decision is not due to any disagreement regarding its operations, policies, or practices.
Starling Oncology, Inc. (STLN) director Brad Hively reported a sale of company stock. On August 21, 2026, he sold 298,853 shares of Starling Oncology Common Stock in a transaction coded as a sale in open market or private transaction. The reported price of $6.5126 per share is a weighted average for multiple trades executed between $6.37 and $6.75 per share. After this transaction, Hively directly holds 411,976 shares of Starling Oncology common stock. The filing affirms that the transaction was effected under a Rule 10b5-1 trading plan.
Starling Oncology, Inc. (STLN) disclosed that its wholly owned subsidiary, Starling Oncology Management, LLC, entered into a new Revolving Loan Agreement with Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL. The facility provides a revolving line of credit with an aggregate principal commitment of up to $25 million, intended to offer additional financial flexibility for working capital and general corporate purposes.
The revolver is secured by a first-priority security interest in substantially all of the subsidiary’s collateral and matures on August 20, 2029. Borrowing availability is governed by a borrowing base tied to certain accounts receivable and related lockbox arrangements with supported professional corporations. Loans bear interest at Term SOFR plus 3.95%, where Term SOFR is the greater of a three‑month forward-looking SOFR rate and 2.00% per annum, with a 5.00% default-rate premium if an event of default occurs.
Starling Oncology must also pay monthly collateral monitoring and unused line fees, a minimum use fee tied to a $5 million minimum balance, and a termination fee of 3.00%, 2.00%, or 1.00% of the commitment depending on when the facility is terminated. Covenants include customary limits on additional debt, liens, and distributions, and require Maximum Loan Turn Days not to exceed 35 days on a rolling three‑month basis each fiscal quarter beginning with the quarter ending December 31, 2026.
Starling Oncology, Inc. (STLN) received a notice that director Bradford Hively plans a Rule 144 sale of up to 298,853 shares of common stock through Morgan Stanley Smith Barney LLC. The shares have an indicated aggregate market value of $1,954,498.62, with 101,916,115 shares outstanding and an approximate sale date of August 21, 2026. The filing lists prior acquisition methods including open market purchases and restricted stock units.
Starling Oncology, Inc. insider Jorey Chernett, a more-than-10% owner, reported mixed transactions in company securities. On 2026-08-14, Chernett purchased 12,000 shares of common stock at $6.54 per share, bringing direct holdings to 10,660,858 shares. On 2026-08-13, Chernett sold 100 call option contracts on Starling Oncology (each linked to 100 shares, or 10,000 underlying common shares) with a $9.00 exercise price and 19-Feb-2027 expiration, at $6.24 per option. According to a footnote, this option sale is treated as a matchable transaction under Section 16(b), and Chernett intends to disgorge the calculated short-swing profit to the issuer.
Starling Oncology, Inc. reported higher revenue and narrower losses for the three and six months ended June 30, 2026. Total operating revenue reached $161,282 thousand in Q2 and $308,723 thousand year‑to‑date, driven by growth in specialty pharmacy and capitated patient services.
Loss from operations improved to $4,616 thousand in Q2 and $11,129 thousand year‑to‑date, with net loss of $9,789 thousand for the quarter and $12,281 thousand for six months. Operating cash flow turned positive at $9,725 thousand, and cash and equivalents increased to $41,094 thousand. The company remained in a stockholders’ deficit of $24,914 thousand and carried $79,867 thousand of senior secured convertible debt at June 30, 2026, which it repaid in full (approximately $86 million principal) on July 1, 2026.
Starling Oncology, Inc. reported strong Q2 2026 results, with total operating revenue of $161,282 thousand, up from $119,802 thousand a year earlier, and CEO commentary noting revenue grew 35% year over year. Net loss narrowed to $(9,789) thousand and Adjusted EBITDA turned positive at $229 thousand.
For the first six months of 2026, cash provided by operating activities improved to $9,725 thousand from $(15,190) thousand, supporting cash and cash equivalents of $41,094 thousand at June 30, 2026. Management highlighted growth in capitated revenue, which reached $27,974 thousand in Q2, and lives under value-based contracts of 2.1 million.
Reflecting this momentum, the company raised full‑year 2026 guidance, now expecting revenue of $650 to $670 million, gross profit of $105 to $110 million, and Adjusted EBITDA of $2 to $7 million, while reiterating projected Free Cash Flow of $5 to $15 million.
Starling Oncology, Inc., formerly The Oncology Institute, Inc., has changed its corporate name effective July 28, 2026 by filing a Certificate of Amendment in Delaware. Its common stock and warrants continue to trade on Nasdaq, with the common stock ticker changing to STLN.
The company states that the name and symbol changes do not affect stockholder rights and that no stockholder action is required. A related press release explains that the rebrand reflects the evolution into an integrated, value-based oncology platform serving about 2.1 million patients through more than 400 clinicians at over 100 clinics across five states.
Kaushal Mohit reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. director Kaushal Mohit received a grant of 33,133 restricted stock units (RSUs) of common stock on July 27, 2026. Each RSU entitles him to one share of common stock upon settlement.
The RSUs vest in full at the company’s 2027 annual meeting of stockholders, subject to his continued service with the company on the vesting date. Following this award, his reported direct holdings total 205,716 shares of common stock.
McGeorge Anne reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. reported that director Anne McGeorge received a grant of 41,165 restricted stock units (RSUs) of common stock. Each RSU entitles her to one share upon settlement and vests in full on the date of the company’s 2027 annual meeting of stockholders, subject to her continued service. Following this award, her direct holdings total 332,535 shares of common stock.